Evidence map›Paper›PMID 28956123›Full record

Trial reportEuropean radiology2018

The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.

Roland M Martens, Arianne Bechten, Silvia Ingala, Ronald A van Schijndel, Vania B Machado, Marcus C de Jong, Esther Sanchez, Derk Purcell, Michael H Arrighi, Robert H Brashear and 2 more

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Accelerated 3D MRI for ARIA monitoring in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Validation of 3- and 5-point severity scales to assess ARIA-E.Alzheimer's & dementia (Amsterdam, Netherlands)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Roland M MartensDepartment of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. ro.martens@vumc.nl.
Arianne BechtenDepartment of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Silvia IngalaDepartment of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Ronald A van SchijndelDepartment of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Vania B MachadoDepartment of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Marcus C de JongDepartment of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Esther SanchezDepartment of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Derk PurcellDepartment of Radiology, California Pacific Medical Center, San Francisco, CA, USA.
Michael H ArrighiJanssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA.
Robert H BrashearJanssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA.
Mike P WattjesDepartment of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Amsterdam Neuroscience · NLJanssen (United States) · USBioClinica (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunotherapeutic treatments targeting amyloid-β plaques in Alzheimer's disease (AD) are associated with the presence of amyloid-related imaging abnormalities with oedema or effusion (ARIA-E), whose detection and classification is crucial to evaluate subjects enrolled in clinical trials. PURPOSE: To investigate the applicability of subtraction MRI in the ARIA-E detection using an established ARIA-E-rating scale.

methodsWe included 75 AD patients receiving bapineuzumab treatment, including 29 ARIA-E cases. Five neuroradiologists rated their brain MRI-scans with and without subtraction images. The accuracy of evaluating the presence of ARIA-E, intraclass correlation coefficient (ICC) and specific agreement was calculated.

resultsSubtraction resulted in higher sensitivity (0.966) and lower specificity (0.970) than native images (0.959, 0.991, respectively). Individual rater detection was excellent. ICC scores ranged from excellent to good, except for gyral swelling (moderate). Excellent negative and good positive specific agreement among all ARIA-E imaging features was reported in both groups. Combining sulcal hyperintensity and gyral swelling significantly increased positive agreement for subtraction images.

conclusionSubtraction MRI has potential as a visual aid increasing the sensitivity of ARIA-E assessment. However, in order to improve its usefulness isotropic acquisition and enhanced training are required. The ARIA-E rating scale may benefit from combining sulcal hyperintensity and swelling. KEY POINTS: • Subtraction technique can improve detection amyloid-related imaging-abnormalities with edema/effusion in Alzheimer's patients. • The value of ARIA-E detection, classification and monitoring using subtraction was assessed. • Validation of an established ARIA-E rating scale, recommendations for improvement are reported. • Complementary statistical methods were employed to measure accuracy, inter-rater-reliability and specific agreement.

Indexed as

AgedAlzheimer DiseaseAmyloidosisAntibodies, Monoclonal, HumanizedBrainBrain EdemaDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesHumansInjections, IntravenousMagnetic Resonance ImagingMaleReproducibility of ResultsROC CurveAntibodies, Monoclonal, HumanizedbapineuzumabAlzheimer's disease (AD)Amyloid beta (Aβ)ARIA (amyloid-related imaging abnormalities)ImmunotherapyMRI (magnetic resonance imaging)

Identifiers

PMID28956123
PMCPMC5811582
OpenAlexW2757625126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.